Company intelligence / Profile preview

PrognomiQ

San Mateo, California, United Statesprognomiq.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

PrognomiQ has reported promising results from the largest deep multi-omics study to date for early-stage lung cancer detection. Their liquid biopsy platform demonstrates high sensitivity/specificity in detecting early-stage disease. A 15,000-subject prospective study was initiated in 2023 to support regulatory registration of their lead IVD product. Early data also presented for pancreatic cancer.

Therapeutic areas: OncologyImmunology
Modalities: Multiomics-based diagnosticsProteomicsGenomicsMetabolomicsEpigenomicsTranscriptomicsLiquid Biopsy
Industry: Molecular Diagnostics

Partnerships

Seer (technology/platform partner)strategic investor from Diagnostics segment involved but not named publicly

Beyond the preview

Go deeper on PrognomiQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrognomiQ.

Explore the full profile